A citation-based method for searching scientific literature

Chadi G Abdallah, Lynnette A Averill, Ralitza Gueorguieva, Selin Goktas, Prerana Purohit, Mohini Ranganathan, Mohamed Sherif, Kyung-Heup Ahn, Deepak Cyril D'Souza, Richard Formica, Steven M Southwick, Ronald S Duman, Gerard Sanacora, John H Krystal. Neuropsychopharmacology 2020
Times Cited: 56







List of co-cited articles
754 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.
Nanxin Li, Boyoung Lee, Rong-Jian Liu, Mounira Banasr, Jason M Dwyer, Masaaki Iwata, Xiao-Yuan Li, George Aghajanian, Ronald S Duman. Science 2010
64

Antidepressant effects of ketamine in depressed patients.
R M Berman, A Cappiello, A Anand, D A Oren, G R Heninger, D S Charney, J H Krystal. Biol Psychiatry 2000
51

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Carlos A Zarate, Jaskaran B Singh, Paul J Carlson, Nancy E Brutsche, Rezvan Ameli, David A Luckenbaugh, Dennis S Charney, Husseini K Manji. Arch Gen Psychiatry 2006
41

NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.
Anita E Autry, Megumi Adachi, Elena Nosyreva, Elisa S Na, Maarten F Los, Peng-fei Cheng, Ege T Kavalali, Lisa M Monteggia. Nature 2011
41

NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
Panos Zanos, Ruin Moaddel, Patrick J Morris, Polymnia Georgiou, Jonathan Fischell, Greg I Elmer, Manickavasagom Alkondon, Peixiong Yuan, Heather J Pribut, Nagendra S Singh,[...]. Nature 2016
803
41

Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure.
Nanxin Li, Rong-Jian Liu, Jason M Dwyer, Mounira Banasr, Boyoung Lee, Hyeon Son, Xiao-Yuan Li, George Aghajanian, Ronald S Duman. Biol Psychiatry 2011
721
30

Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.
Sungho Maeng, Carlos A Zarate, Jing Du, Robert J Schloesser, Joseph McCammon, Guang Chen, Husseini K Manji. Biol Psychiatry 2008
819
28


Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants.
Ronald S Duman, George K Aghajanian, Gerard Sanacora, John H Krystal. Nat Med 2016
677
26

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.
Panos Zanos, Ruin Moaddel, Patrick J Morris, Lace M Riggs, Jaclyn N Highland, Polymnia Georgiou, Edna F R Pereira, Edson X Albuquerque, Craig J Thomas, Carlos A Zarate,[...]. Pharmacol Rev 2018
359
21

Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.
Nolan R Williams, Boris D Heifets, Christine Blasey, Keith Sudheimer, Jaspreet Pannu, Heather Pankow, Jessica Hawkins, Justin Birnbaum, David M Lyons, Carolyn I Rodriguez,[...]. Am J Psychiatry 2018
205
21

Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2R,6R)-hydroxynorketamine.
Kenichi Fukumoto, Manoela V Fogaça, Rong-Jian Liu, Catharine Duman, Taro Kato, Xiao-Yuan Li, Ronald S Duman. Proc Natl Acad Sci U S A 2019
83
21

Mechanisms of ketamine action as an antidepressant.
P Zanos, T D Gould. Mol Psychiatry 2018
313
21

The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
Samuel T Wilkinson, Elizabeth D Ballard, Michael H Bloch, Sanjay J Mathew, James W Murrough, Adriana Feder, Peter Sos, Gang Wang, Carlos A Zarate, Gerard Sanacora. Am J Psychiatry 2018
273
19

R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects.
C Yang, Y Shirayama, J-c Zhang, Q Ren, W Yao, M Ma, C Dong, K Hashimoto. Transl Psychiatry 2015
307
17

Intravenous arketamine for treatment-resistant depression: open-label pilot study.
Gustavo C Leal, Igor D Bandeira, Fernanda S Correia-Melo, Manuela Telles, Rodrigo P Mello, Flavia Vieira, Cassio S Lima, Ana Paula Jesus-Nunes, Lívia N F Guerreiro-Costa, Roberta F Marback,[...]. Eur Arch Psychiatry Clin Neurosci 2021
80
17

Ketamine: A Paradigm Shift for Depression Research and Treatment.
John H Krystal, Chadi G Abdallah, Gerard Sanacora, Dennis S Charney, Ronald S Duman. Neuron 2019
125
17

Mechanistic Target of Rapamycin-Independent Antidepressant Effects of (R)-Ketamine in a Social Defeat Stress Model.
Chun Yang, Qian Ren, Youge Qu, Ji-Chun Zhang, Min Ma, Chao Dong, Kenji Hashimoto. Biol Psychiatry 2018
116
17

Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation.
R N Moda-Sava, M H Murdock, P K Parekh, R N Fetcho, B S Huang, T N Huynh, J Witztum, D C Shaver, D L Rosenthal, E J Alway,[...]. Science 2019
210
17

Acute suppression of spontaneous neurotransmission drives synaptic potentiation.
Elena Nosyreva, Kristen Szabla, Anita E Autry, Alexey G Ryazanov, Lisa M Monteggia, Ege T Kavalali. J Neurosci 2013
163
17

BDNF release is required for the behavioral actions of ketamine.
Ashley E Lepack, Manabu Fuchikami, Jason M Dwyer, Mounira Banasr, Ronald S Duman. Int J Neuropsychopharmacol 2014
217
17

Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex.
Rong-Jian Liu, Francis S Lee, Xiao-Yuan Li, Francis Bambico, Ronald S Duman, George K Aghajanian. Biol Psychiatry 2012
266
17

Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
James W Murrough, Andrew M Perez, Sarah Pillemer, Jessica Stern, Michael K Parides, Marije aan het Rot, Katherine A Collins, Sanjay J Mathew, Dennis S Charney, Dan V Iosifescu. Biol Psychiatry 2013
458
17

Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
James W Murrough, Dan V Iosifescu, Lee C Chang, Rayan K Al Jurdi, Charles E Green, Andrew M Perez, Syed Iqbal, Sarah Pillemer, Alexandra Foulkes, Asim Shah,[...]. Am J Psychiatry 2013
666
16

Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.
Chadi G Abdallah, Gerard Sanacora, Ronald S Duman, John H Krystal. Annu Rev Med 2015
222
16

Synaptic dysfunction in depression: potential therapeutic targets.
Ronald S Duman, George K Aghajanian. Science 2012
758
16

Ketamine blocks bursting in the lateral habenula to rapidly relieve depression.
Yan Yang, Yihui Cui, Kangning Sang, Yiyan Dong, Zheyi Ni, Shuangshuang Ma, Hailan Hu. Nature 2018
349
16

GABA interneurons are the cellular trigger for ketamine's rapid antidepressant actions.
Danielle M Gerhard, Santosh Pothula, Rong-Jian Liu, Min Wu, Xiao-Yuan Li, Matthew J Girgenti, Seth R Taylor, Catharine H Duman, Eric Delpire, Marina Picciotto,[...]. J Clin Invest 2020
89
16

(R)-Ketamine Shows Greater Potency and Longer Lasting Antidepressant Effects Than Its Metabolite (2R,6R)-Hydroxynorketamine.
Chun Yang, Youge Qu, Masahito Abe, Dai Nozawa, Shigeyuki Chaki, Kenji Hashimoto. Biol Psychiatry 2017
99
14

Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
D Jeffrey Newport, Linda L Carpenter, William M McDonald, James B Potash, Mauricio Tohen, Charles B Nemeroff. Am J Psychiatry 2015
341
14

The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?
Chadi G Abdallah, Gerard Sanacora, Ronald S Duman, John H Krystal. Pharmacol Ther 2018
94
14

Ketamine Treatment and Global Brain Connectivity in Major Depression.
Chadi G Abdallah, Lynnette A Averill, Katherine A Collins, Paul Geha, Jaclyn Schwartz, Christopher Averill, Kaitlin E DeWilde, Edmund Wong, Alan Anticevic, Cheuk Y Tang,[...]. Neuropsychopharmacology 2017
140
14




Common Neurotransmission Recruited in (R,S)-Ketamine and (2R,6R)-Hydroxynorketamine-Induced Sustained Antidepressant-like Effects.
Thu Ha Pham, Céline Defaix, Xiaoming Xu, Shi-Xian Deng, Nicolas Fabresse, Jean-Claude Alvarez, Donald W Landry, Rebecca A Brachman, Christine A Denny, Alain M Gardier. Biol Psychiatry 2018
73
14

A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.
Jaskaran B Singh, Maggie Fedgchin, Ella J Daly, Peter De Boer, Kimberly Cooper, Pilar Lim, Christine Pinter, James W Murrough, Gerard Sanacora, Richard C Shelton,[...]. Am J Psychiatry 2016
257
14

GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine.
Oliver H Miller, Lingling Yang, Chih-Chieh Wang, Elizabeth A Hargroder, Yihui Zhang, Eric Delpire, Benjamin J Hall. Elife 2014
189
14

Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects.
G M I Chowdhury, J Zhang, M Thomas, M Banasr, X Ma, B Pittman, L Bristow, E Schaeffer, R S Duman, D L Rothman,[...]. Mol Psychiatry 2017
114
14


Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.
Rebecca B Price, Matthew K Nock, Dennis S Charney, Sanjay J Mathew. Biol Psychiatry 2009
392
14

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Ella J Daly, Madhukar H Trivedi, Adam Janik, Honglan Li, Yun Zhang, Xiang Li, Rosanne Lane, Pilar Lim, Anna R Duca, David Hough,[...]. JAMA Psychiatry 2019
160
14

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Madhukar H Trivedi, A John Rush, Stephen R Wisniewski, Andrew A Nierenberg, Diane Warden, Louise Ritz, Grayson Norquist, Robert H Howland, Barry Lebowitz, Patrick J McGrath,[...]. Am J Psychiatry 2006
12

Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine.
Kenichi Fukumoto, Hidetoh Toki, Michihiko Iijima, Takashi Hashihayata, Jun-Ichi Yamaguchi, Kenji Hashimoto, Shigeyuki Chaki. J Pharmacol Exp Ther 2017
124
12

R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine.
Ji-Chun Zhang, Su-Xia Li, Kenji Hashimoto. Pharmacol Biochem Behav 2014
185
12

Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.
Jaskaran B Singh, Maggie Fedgchin, Ella Daly, Liwen Xi, Caroline Melman, Geert De Bruecker, Andre Tadic, Pascal Sienaert, Frank Wiegand, Husseini Manji,[...]. Biol Psychiatry 2016
205
12

(2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice.
Jun-Ichi Yamaguchi, Hidetoh Toki, Youge Qu, Chun Yang, Hiroyuki Koike, Kenji Hashimoto, Akiko Mizuno-Yasuhira, Shigeyuki Chaki. Neuropsychopharmacology 2018
51
13


Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants.
Todd D Gould, Carlos A Zarate, Scott M Thompson. Annu Rev Pharmacol Toxicol 2019
59
12

Side-effects associated with ketamine use in depression: a systematic review.
Brooke Short, Joanna Fong, Veronica Galvez, William Shelker, Colleen K Loo. Lancet Psychiatry 2018
189
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.